Clinical Scorecard: Body Mass Index and Prognostic Nutritional Index as Indicators of Treatment Adherence and Survival Outcomes in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Undergoing Sequential Chemoradiotherapy

At a Glance

Key Highlights

• Head and neck cancers account for 5-6% of male cancers in the U.S., with significant mortality rates.
• Induction chemotherapy may enhance the efficacy of subsequent chemoradiotherapy, particularly in advanced stages.
• Toxicity from treatment can limit quality of life and survival outcomes, necessitating careful monitoring.
• BMI and PNI are evaluated as predictors of treatment completion and survival, with implications for patient management.

Guideline-Based Recommendations

Diagnosis

Management

• Administer three cycles of induction chemotherapy followed by concurrent chemoradiotherapy, adjusting based on patient response and toxicity.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Patients diagnosed with locally advanced HNSCC, excluding those with previous chemotherapy or radiotherapy, inflammatory diseases, or second malignancies.

Clinical Best Practices

• Utilize a multidisciplinary approach for treatment planning, ensuring comprehensive care.
• Assess inflammatory biomarkers prior to treatment to predict outcomes and tailor therapy.
• Adjust chemotherapy doses according to international guidelines, considering patient-specific factors.

Related Resources & Content

• Pignon et al. MACH-NC meta-analysis